Literature DB >> 16399958

Best practices: An initiative to curtail the use of antipsychotic polypharmacy in a state psychiatric hospital.

Vijayalakshmy Patrick1, Steven J Schleifer, Jeffry R Nurenberg, Kenneth J Gill.   

Abstract

A performance improvement initiative was undertaken at a state psychiatric hospital to reduce antipsychotic polypharmacy. Data from physicians' order forms were used to document the prescribing practices of 14 psychiatrists in November 2001 and in August 2002. After baseline data were collected, the chief of psychiatry met with each psychiatrist to compare his or her prescribing data with data of anonymous peers. The chief also asked all psychiatrists to decrease antipsychotic polypharmacy by at least 10 percent. Antipsychotic polypharmacy fell significantly--from 42 percent of patients treated with antipsychotics in November 2001 to 31 percent in August 2002. Higher utilizers of polypharmacy at baseline continued to be high utilizers at follow-up. Less antipsychotic polypharmacy was not associated with more use of other psychotropic medications. The findings suggest that initiatives that involve the focused attention of leadership and only a modest investment of effort can result in significant change in prescribing practices in a state hospital.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16399958     DOI: 10.1176/appi.ps.57.1.21

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  13 in total

1.  Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.

Authors:  Surendra P Singh; Vidhi Singh
Journal:  CNS Drugs       Date:  2011-10-01       Impact factor: 5.749

Review 2.  A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy.

Authors:  William G Honer; Ric M Procyshyn; Eric Y H Chen; G William MacEwan; Alasdair M Barr
Journal:  J Psychiatry Neurosci       Date:  2009-11       Impact factor: 6.186

3.  Adverse effects of psychotropic medications in children: predictive factors.

Authors:  Ajit Ninan; Shannon L Stewart; Laura A Theall; Shehan Katuwapitiya; Chester Kam
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2014-09

Review 4.  Antipsychotic polypharmacy in schizophrenia: benefits and risks.

Authors:  Thomas R E Barnes; Carol Paton
Journal:  CNS Drugs       Date:  2011-05       Impact factor: 5.749

Review 5.  Variation of the prevalence of pediatric polypharmacy: A scoping review.

Authors:  Courtney Baker; James A Feinstein; Xuan Ma; Shari Bolen; Neal V Dawson; Negar Golchin; Alexis Horace; Lawrence C Kleinman; Sharon B Meropol; Elia M Pestana Knight; Almut G Winterstein; Paul M Bakaki
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-02-06       Impact factor: 2.890

Review 6.  Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice.

Authors:  Christoph U Correll; Juan A Gallego
Journal:  Psychiatr Clin North Am       Date:  2012-07-24

Review 7.  Conceptual and methodological issues in the design of clinical trials of antipsychotics for the treatment of schizophrenia.

Authors:  William G Honer; Allen E Thornton; Megan Sherwood; G William MacEwan; Tom S Ehmann; Richard Williams; Lili C Kopala; Ric Procyshyn; Alasdair M Barr
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

8.  Significance and Factors Associated with Antipsychotic Polypharmacy Utilization Among Publicly Insured US Adults.

Authors:  Marcela Horvitz-Lennon; Rita Volya; Katya Zelevinsky; Mimi Shen; Julie M Donohue; Andrew Mulcahy; Sharon-Lise T Normand
Journal:  Adm Policy Ment Health       Date:  2021-05-19

9.  Previous hospital admissions and disease severity predict the use of antipsychotic combination treatment in patients with schizophrenia.

Authors:  Albert Bolstad; Ole A Andreassen; Jan I Røssberg; Ingrid Agartz; Ingrid Melle; Lars Tanum
Journal:  BMC Psychiatry       Date:  2011-08-03       Impact factor: 3.630

10.  Pharmacotherapy of schizophrenic patients: preponderance of off-label drug use.

Authors:  David Pickar; Jessie Vinik; John J Bartko
Journal:  PLoS One       Date:  2008-09-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.